Further research found that combining a MEK inhibitor, binimetinib, with a BRAF inhibitor, encorafenib, as opposed to a BRAF inhibitor alone, yielded long term benefit in progression free survival in patients with melanoma [94]. This evidence concerns the gene MAP2K7 and melanoma.